Biopharma News

Sep 05, 2017
By BioPharm International Editors
Novartis has appointed Dr. Vasant Narasimhan as CEO.
Sep 01, 2017
By BioPharm International Editors
With this acquisition, Oncurious, a Belgium-based biotechnology company, will gain a pipeline of immune-oncology drug candidates.
Sep 01, 2017
By BioPharm International Editors
Bristol-Myers Squibb (BMS) and Daiichi Sankyo announced a collaboration to evaluate the combination of Opdivo (nivolumab) and antibody drug conjugate (ADC) DS-8201 for treating breast and bladder cancers.
Aug 31, 2017
By BioPharm International Editors
MilliporeSigma announced a collaboration with Angiex, a biotechnology start-up, to support the development of Angiex’s lead oncology antibody drug candidate to clinical use.
Aug 31, 2017
By BioPharm International Editors
Hospira, a Pfizer company, is voluntarily recalling one lot of vancomycin hydrochloride for injection, USP, 750 mg/vial because of glass within a single vial.
Aug 30, 2017
By BioPharm International Editors
Genentech’s Actemra (tocilizumab), a rheumatoid arthritis drug, has been approved for a new indication, treating CAR T cell-induced cytokine release syndrome (CRS), a side effect of CAR T cell therapy.
Aug 30, 2017
By BioPharm International Editors
FDA issued a Refusal to File letter to Acorda Therapeutics, citing insufficiently complete information in the company’s new drug application for its investigational Parkinson’s disease drug.
Aug 29, 2017
By BioPharm International Editors
AstraZeneca and Takeda will partner to develop and commercialize MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD).
Aug 29, 2017
By BioPharm International Editors
Gilead will gain a robust pipeline of cell therapy products, with one lead candidate, a CAR T therapy, anticipated to gain FDA approval in the fourth quarter.
Aug 28, 2017
By BioPharm International Editors
The acquisition of Protein Sciences, a vaccines biotechnology company, strengthens Sanofi’s influenza vaccines portfolio.
native1_300x100
lorem ipsum